NMRA
NASDAQ · Pharmaceuticals
Neumora Therapeutics Inc
$1.63
-0.01 (-0.61%)
Open$1.64
Previous Close$1.64
Day High$1.68
Day Low$1.62
52W High$3.65
52W Low$0.83
Volume—
Avg Volume718.5K
Market Cap303.87M
P/E Ratio—
EPS$-1.33
SectorPharmaceuticals
Analyst Ratings
Strong Buy
15 analysts
Price Target
+963.8% upside
Current
$1.63
$1.63
Target
$17.34
$17.34
$11.85
$17.34 avg
$21.76
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 131.86M | 126.94M | 118.45M |
| Net Income | 20.35M | 17.55M | 19.05M |
| Profit Margin | 15.4% | 13.8% | 16.1% |
| EBITDA | 29.65M | 29.50M | 31.41M |
| Free Cash Flow | 15.46M | 12.66M | 10.19M |
| Rev Growth | -7.9% | +5.6% | -2.9% |
| Debt/Equity | 0.29 | 0.31 | 0.30 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,185.71 | -0.52% | 41.4 | 1.11T |
| JNJ | Johnson & Johnson | $259.24 | +0.88% | 29.3 | 617.08B |
| MRK | Merck & Co. Inc. | $128.58 | +0.16% | 99.4 | 315.27B |
| PFE | Pfizer Inc. | $26.76 | +2.14% | 34.8 | 150.87B |
| BMY | Bristol-Myers Squibb Co | $64.72 | +0.89% | 14.1 | 131.10B |
| ZTS | Zoetis Inc | $72.66 | -5.97% | 12.3 | 32.39B |